FACCHETTI, FLORIANA
FACCHETTI, FLORIANA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
A response guided approach to peginterferon alfa-2a therapy based on HBsAg levels at weeks 12 and 24 improves response rates in HBeAG-negative, genotype D chronic hepatitis B patients
2011 P. Lampertico, M. Vigano, G.G. Di Costanzo, E. Sagnelli, M. Fasano, V. Di Marco, S. Boninsegna, P. Farci, S.R. Fargion, T. Giuberti, V. Rothe, L. Regep, B. Massetto, F. Facchetti, A. Testa
Allelic inhibition of displacement activity : a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms
2013 E. Galmozzi, F. Facchetti, E. Degasperi, A. Aghemo, P. Lampertico
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide
2020 L. Roade, A. Loglio, M. Borghi, M. Riveiro-Barciela, R. Soffredini, F. Facchetti, D. di Paolo, D. Tabernero, G. Lunghi, R. Esteban, M. Buti, P. Lampertico
BRAF V599E mutation occurs in Spitz and Reed nevi
2006 C. La Porta, R. Cardani, F. Facchetti, P. Presicce, S. Rao, E. Privitera, C. Clemente, M. C. Mihm
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 E. Degasperi, M. Anolli, S.C. UCEDA RENTERIA, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim, P. Lampertico
Cancer stem cells and therapeutic perspectives
2006 E. Galmozzi, F. Facchetti, C.A.M. La Porta
CARATTERIZZAZIONE MOLECOLARE DELLA FARMACO-RESISTENZA IN PAZIENTI NAIVE CON EPATITE CRONICA B TRATTATI CON ENTECAVIR
2012 F. Facchetti
CD133 positive cellular population in human melanoma
2007 C. Anna Maria la Porta, E. Monzani, F. Facchetti, E. Galmozzi, E. Corsini, A. Benetti, C. Cavazzin, A. Gritti, A.A.M. Piccinini, M. Santinami, E. Parati, G. Alessandri
CD133 postive cellular population in human melanoma
2007 C. La Porta, E. Monzani, E. Corsini, F. Facchetti, E. Galmozzi, A. Benetti, C. Cavazzin, A. Gritti, A.A. Piccinini, M. Santinami, E. Parati, G. Alessandri
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients
2021 A. Papatheodoridi, A. Chatzigeorgiou, L. Chrysavgis, P. Lembessis, A. Loglio, F. Facchetti, E. Cholongitas, M. Koutsilieris, P. Lampertico, G. Papatheodoridis
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B
2018 A. Loglio, M. Iavarone, G. Grossi, M. Viganò, M.G. Rumi, F. Facchetti, G. Lunghi, A. Sangiovanni, M. Colombo, P. Lampertico
Defect of regulatory T cells in patients with Omenn syndrome
2010 B. Cassani, L. Poliani, D. Moratto, C. Sobacchi, V. Marrella, L. Imperatori, D. Vairo, A. Plebani, S. Giliani, F. Facchetti, F. Porta, L.D. Notarangelo, A.V.A.R. Badolato
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
2019 A. Dodero, A. Guidetti, A. Tucci, F. Barretta, M. Novo, L. Devizzi, A. Re, A. Passi, A. Pellegrinelli, G. Pruneri, R. Miceli, A. Testi, M. Pennisi, M.C. Di Chio, P. Matteucci, C. Carniti, F. Facchetti, G. Rossi, P. Corradini
Effect of a caloric restriction regimen on the angiogenic capacity of aorta and on the expression of endothelin-1 during ageing
2007 F. Facchetti, E. Monzani, G. Cavallini, E. Bergamini, C.A.M. La Porta
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
2019 M. Vigano, A. Loglio, S. Labanca, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, A. Tucci, G. Taliani, M. Fasano, S. Fagiuoli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, V. Occhipinti, F. Facchetti, G. Grossi, M. Rumi, P. Lampertico
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice
2009 P. Lampertico, M. Viganò, F. Facchetti, E. Minola, F. Suter, M. Puoti, M. Brunetto, B. Coco, S.R. Fargion, E. Fatta, P. Del Poggio, M. Pozzi, M. Milanese, G. Colloredo, S. Fagiuoli, L. Pasulo, M.A. Iavarone, M. Colombo
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice
2009 P. Lampertico, M. Viganò, F. Facchetti, E. Minola, F. Suter, M. Puoti, M. Brunetto, B. Coco, S.R. Fargion, E. Fatta, P. Del Poggio, M. Pozzi, M. Milanese, G. Colloredo, S. Fagiuoli, L. Pasulo, M.A. Iavarone, M. Colombo
Effectiveness of Entecavir for the treatment of NUC-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice
2008 P. Lampertico, M. Viganò, F. Facchetti, M. Puoti, E. Minola, F. Suter, M. Brunetto, B. Coco, S. Fargion, E. Fatta, P. Del Poggio, M. Pozzi, M. Milanese, G. Colloredo, S. Fagiuoli, L. Pasulo, M. Colombo
Entecavir for nuc-naïve chronic hepatitis B patients in clinical practice : long-term effectiveness from a large multicenter cohort study in 376 patients
2009 P. Lampertico, M. Viganò, F. Facchetti, F. Suter, E. Minola, O. Fracassetti, G. Carosi, M. Puoti, G. Rizzardini, G. Gubertini, C. Magni, G. Antonucci, A. Testa, P. Del Poggio, S. Fargion, E. Fatta, M.R. Brunetto, B. Coco, A. Colli, M. Andreoletti, T.A. Santantonio, M. Fasano, G. Colloredo, L. Pasulo, M. Milanese, N. Terreni, M. Borzio, G. Lunghi, R. Soffredini, M. Colombo
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study
2009 P. Lampertico, M. Viganò, F. Facchetti, F. Suter, E. Minola, O. Fracassetti, G. Carosi, M. Puoti, G. Rizzardini, G. Gubertini, C. Magni, P. Del Poggio, S. Fargion, E. Fatta, M. Brunetto, B. Coco, G. Colloredo, M. Pozzi, M. Milanese, S. Fagiuoli, L. Pasulo, M. Borzio, M. Quagliuolo, M. Iavarone, G. Lunghi, M. Colombo